[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 061″]
David Nierengarten, Managing Director, Wedbush Securities, explains how public market cycles could hit biotech and ophthalmology companies.
David Nierengarten, PhD
David Nierengarten is a senior biotechnology equity analyst with Wedbush Securities, mainly covering development-stage therapeutic companies. He began his career on the financial side of biotechnology at a venture capital firm that focused on early-stage therapeutic and medical device companies.